Carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) for initial therapy of newly diagnosed multiple myeloma (NDMM): Results of ENDURANCE (E1A11) phase III trial.

Shaji Kumar,Susanna Jacobus,Adam D. Cohen,Matthias Weiss,Natalie S. Callander,Avina A. Singh,Terri L. Parker,Alex R. Menter,Xuezhong Yang,Benjamin M. Parsons,Pankaj Kumar,Prashant Kapoor,Aaron S. Rosenberg,Jeffrey A. Zonder,Edward A. Faber,Sagar Lonial,Paul G. Richardson,Robert Z. Orlowski,Lynne I. Wagner,S. Vincent Rajkumar

Carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) for initial therapy of newly diagnosed multiple myeloma (NDMM): Results of ENDURANCE (E1A11) phase III trial.

2020

LBA3Background: Bortezomib (btz) combined with lenalidomide (len) and dexamethasone (dex) (VRd) is a standard initial therapy for NDMM. Carfilzomib (cfz), a next-generation proteasome inhibitor, in...

Keywords:

Carfilzomib
initial therapy
Multiple myeloma
newly diagnosed
Medicine
Proteasome inhibitor
Dexamethasone
Lenalidomide
Oncology
Internal medicine
Pathology
Bortezomib

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations